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ARTICLE
Long wavelength single photon like driven
photolysis via triplet triplet annihilation
Ling Huang1, Le Zeng1, Yongzhi Chen1, Nuo Yu1, Lei Wang 1, Kai Huang 1, Yang Zhao1 & Gang Han 1✉
Photolysis has enabled the occurrence of numerous discoveries in chemistry, drug discovery
and biology. However, there is a dearth of efficient long wavelength light mediated photolysis.
Here, we report general and efficient long wavelength single photon method for a wide array
of photolytic molecules via triplet-triplet annihilation photolysis. This method is versatile and
“LEGO”-like. The light partners (the photosensitizers and the photolytic molecules) can be
energetically matched to adapt to an extensive range of electromagnetic spectrum wave-
lengths and the diversified chemical structures of photoremovable protecting groups, pho-
tolabile linkages, as well as a broad array of targeted molecules. Compared to the existing
photolysis methods, our strategy of triplet-triplet annihilation photolysis not only exhibits
superior reaction yields, but also resolves the photodamage problem, regardless of whether
they are single photon or multiple photon associated. Furthermore, the biological promise of
this “LEGO” system was illustrated via developing ambient air-stable nanoparticles capable of
triplet-triplet annihilation photolysis.
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Photolysis is a chemical reaction in which a chemical com-pound is broken down by light to allow for non-invasivecontrol of the release and activation of targeted molecules.
Due to the unique and precise spatiotemporal controllability, the
use of photolysis has been a powerful approach that has vast
applications from organic synthesis, drug discovery to numerous
biological areas, such as developmental biology, neuromodula-
tion, as well as cancer treatments. In general, a photolytic mole-
cule (PPG-X) consists of three key components: a target molecule,
a photolabile linkage and a photoremovable protecting group
(PPG). In photolysis, PPG absorbs high-energy photons and then
transitions to an excited state, causing photolabile linkage to
break down and the subsequent release of targeted molecules.
Unfortunately, most of the existing PPGs, such as coumarin
(Cou), anthracene (An) and perylene (Py), boron-dipyrromethene
(BDP) groups only respond to high-energy short wavelength light
excitation for subsequent single photon photolytic reactions
(Fig. 1a)1. However, the use of short wavelength light for photo-
lysis has inherent drawbacks. For instance, the shallow penetration
of such short wavelength light through colored reaction solvents
or media leads to poor photolytic reaction yields, especially in
large-scale chemical reactions2. In addition, short wavelength
photons cause the rapid photodamage and photobleaching of
PPGs1,2. Moreover, in regard to photolysis applications in biology,
the term “photouncaging” has been coined to describe the tech-
nique of using light to remove the PPGs and activate biological
compounds so as to noninvasively probe different biological
processes, neuronal connections, as well as to develop disease
treatments3. However, photouncaging using conventional short-
wavelength light also comes along with a series of serious pro-
blems, such as inevitable phototoxicity and shallow tissue pene-
tration depths4. Ideally, these problems can be overcome by the
use of lower energy long wavelength light (including far red light
and near infrared light), which has much higher penetration depth
through various media and biological tissue5.
To date, there are only a pair of state-of-the-art long wave-
length activation photolytic methods in the reported literature.
For example, the femtosecond pulsed two-photon laser can be
used to remove PPGs6. However, this process is quite inadequate
for photolysis, as the two-photon absorption cross-sectional area
of PPGs is quite weak and the reactions can only take place in the
tiny area of the laser focal point (Fig. 1b)1. Meanwhile, lanthanide
ion-doped upconversion nanoparticles (UCNPs)-assisted photo-
lysis have emerged as an appealing method7. Yet, owing to low
absorption and emission cross-sections, the lanthanide ion-doped
UCNPs typically suffer from the need for high power light
excitation (101–104W cm−2) and inherently low quantum
yields8,9. In addition, upconversion luminescence resonance
energy transfer (LRET) from inorganic UCNPs to conjugated
PPGs is generally inefficient (Fig. 1c).
In this study, we report on a highly effective and general long
wavelength single photon-driven photolysis method via
triplet–triplet annihilation (TTA). The detailed mechanism for our
TTA-mediated photolysis (TTAP) is delineated in Fig. 1d. As
depicted, photosensitizers (Sen) can absorb low-energy long wave-
length photons, reach their singlet excited state (1[Sen]*) and sub-
sequently populate their long-lived triplet excited state (3[Sen]*)
through rapid intersystem crossing (ISC). The lifetime of this
photosensitizer triplet excited state is long enough to allow colli-
sions of the targeted PPGs-X to occur. The energy of 3[Sen]* can
thus be efficiently transferred to PPGs-X. Consequently, the TTA of
1[PPGs-X]* drives photolytic reactions to take place, thus breaking
down the photolabile linkage and releasing and activating the tar-
geted molecules. Because of the much greater light absorption of
photosensitizers than PPGs themselves and the highly efficient
triplet–triplet energy transfer (TTET) from photosensitizers to
PPGs-X, we envision our long wavelength single photon-driven
TTAP method to outperform the existing short-wavelength single
photon direct activation and the above-mentioned long wavelength
activation methods.
Results
The general rules to design effective TTAP “LEGO” systems. In
particular, in the proposed TTAP process, there are two general
rules to design effective TTAP “LEGO” systems. Firstly, the PPGs
should have a lower laying triplet excited state than that of the
triplet excited state of the photosensitizer (3[PPGs]* < 3[Sen]*),
allowing the efficient TTET process to occur from Sen to PPGs.
Secondly, the doubled energy of the triplet excited state of the
PPGs should be higher than that of the singlet excited state of the
PPGs (2×3[PPGs]* > 1[PPGs]*), enabling the ultimate TTA to
take place (Fig. 1d)10–12.
Versatile, high-performing, and “LEGO”-like TTAP light
partners. To verify our hypothesis, we began our TTAP investi-
gation with a widely used PPG from an ultraviolet light absorbing
Cou group (T1= 2.18 eV) (Supplementary Table 1)13. Here, due
to its broad presence in pharmaceuticals and natural products, in
conjunction with such PPG from Cou group, the ester bond was
tested to see the feasibility of its being used for photolabile linkage
to protect carboxylate (acetic acid) in compound 1 (see below).
After considering the energetic requirements of the TTAP, Ir
(ppy)3 (T1= 2.4 eV) (Supplementary Table 1) was chosen as the
initial coupling photosensitizer partner (Supplementary Fig. 2
and Supplementary Tables 2 and 3)14. The TTET process from Ir
(ppy)3 to compound 1 was studied via Stern−Volmer photo-
luminescence quenching assays under oxygen-free conditions.
When we titrated compound 1 into the Ir(ppy)3 solution, the
phosphorescence decreased dramatically (Supplementary Fig. 3).
The respective Stern−Volmer constants (ksv) were calculated to
be 3.13 × 103M−1. Next, when combining the Ir(ppy)3 with
compound 1, we observed the photolytic product in the yield of
73% under the blue light illumination at characteristic absorption
of Ir(ppy)3 (476 nm, LED, 20 mW cm−2). In contrast, in the
absence of Ir(ppy)3, no photolytic product was observed under
such blue light irradiation, since the PPG of the Cou group
requires ~360 nm ultraviolet light direct activation (Supplemen-
tary Table 4). This experiment clearly validated the feasibility of
our proposed TTAP concept.
Inspired by the above-mentioned TTAP experimental results,
we continued to examine whether this TTAP concept is general
enough to be adapted to a wide spectrum of electron-magnetic
wavelengths (Fig. 1e–h). To do so, we tested a series of long
wavelength absorbing sensitizers, ranging from green (PtOEP),
far-red (PdTPBP) to near infrared light (PtTNP) (Fig. 1e and g), as
well as a broad array of PPGs (An, Py, and BDP) (Fig. 1f and h).
Through extensive analysis of the photophysical properties
(Supplementary Tables 2 and 3), we identified a family of
potential TTAP light partners based on the energetic match
among these sensitizers and PPGs. These new TTAP pairs are: (1)
PtOEP: An; (2) PtOEP: Py; (3) PdTPBP:Py; (4) PdTPBP:BDP; (5)
PtTNP:Py; and (6) PtTNP:BDP (Supplementary Tables 2 and 3,
and Supplementary Fig. 2). To further support our theoretical
spectrum analysis, we then tested the Stern−Volmer constants
(ksv) (Supplementary Figs. 5–15 and Supplementary Tables 5–11)
in regard to all of these selected combinations. As shown in
Supplementary Table 1, compound 2 with PPG of An (T1= 1.77
eV)15 and compound 8 with PPG of perylene (T1= 1.52 eV)16
demonstrate significant quenching of the photoluminescence of
green light-absorbing photosensitizer of PtOEP (T1= 1.92 eV)
(Supplementary Figs. 5 and 7). Meanwhile, for far-red light
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absorbing photosensitizer PdTPBP, compound 7 with PPG of
BDP (T1= 1.49 eV) and compound 8 with PPG of perylene
exhibited obvious quenching effects on the photoluminescence of
PdTPBP (T1= 1.55 eV) (Supplementary Figs. 9 and 10). Moreover,
regarding NIR light absorbing photosensitizer PtTNP, compounds
7 and 8 also show quenching effect on its photoluminescence (T1=
1.43 eV) (Supplementary Fig. 11).
Moreover, the TTA-upconversion (TTA-UC) properties were
studied for these pairs. The TTA-UC spectra of these pairs were
measured in deaerated toluene. The upconversion quantum yields
(ΦUC) were calculated based on the established method in the
literature12. Supplementary Figs. 6 and 8 are the TTA-UC spectra
of green light-activated TTA-pairs of PtOEP: An (compound 2)
and PtOEP:Py (compound 8) under 530 nm (20 mW cm−2) light
illumination. The upconversion quantum yields are determined
to be 8.7% for PtOEP: An (compound 2) and 9.5% for PtOEP: Py
(compound 8). Supplementary Fig. 15a and b are TTA-UC
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Fig. 1 The mechanism of reported state-of-the-art photolytic reactions and the TTAP mechanism in this work. a The reported mechanism of
conventional photolytic mechanism. hv: single photon. b Pulsed two photon laser strategy mechanism for photolytic reaction. 2 hv: two photon. c The
reported lanthanide ion-doped upconversion nanoparticles (UCNPs)-mediated photolytic reaction. LRET luminescence resonance energy transfer. d The
mechanism of triplet–triplet annihilation-mediated photolysis (TTAP, this work). ISC intersystem crossing, TTET triplet–triplet energy transfer, TTA
triplet–triplet annihilation, 1[Sen]* the singlet excited state of the photosensitizer, 3[Sen]* the triplet excited state of the photosensitizer, PPGs-X a
photolytic molecule, PPGs photoremovable protecting groups (BDP, Py, An, and Cou), X targeted molecules (amino acids, anti-inflammatory drugs, anti-
cancer drug, cholesterol), and photolabile linkage (ester bond, carbonate, carbamate). eMolecular structures of photosensitizers, including PtTNP, PdTPBP,
PtOEP, and Ir(ppy)3. f Molecular structures of PPGs, including BDP, Py, An, and Cou moieties. g The normalized UV–vis absorption spectra of
photosensitizers. h The normalized UV–vis absorption spectra of PPGs.
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(compound 8) and PdTPBP:BDP (compound 7) under 650 nm
(20 mW cm−2) light illumination. The upconversion quantum
yields are determined to be 5.8% for PdTPBP:Py (compound 8)
and 8.4% for PdTPBP:BDP (compound 7). Supplementary
Fig. 15c and d are the TTA-UC spectra of the NIR light-
activated TTA pairs of PtTNP:Py (compound 8) and PtTNP:BDP
(compound 7) under 650 nm (20 mW cm−2) light illumination.
The upconversion quantum yields are determined to be 0.05% for
PtTNP:Py (compound 8) and 0.3% for PtTNP:BDP (compound 7).
Furthermore, the upconversion emission for the TTA-pairs is
observed to be power-dependent (Supplementary Figs. 12–14). The
threshold intensities (Ith) are determined to be 25.4mWcm−2 for
PtOEP:An (compound 2), 21.8mWcm−2 for PtOEP:Py (compound
8), 48.1mWcm−2 for PdTPBP:Py (compound 8), 46.7mWcm−2
for PdTPBP:BDP (compound 7), 94.5mWcm−2 for PtTNP:Py
(compound 8), and 119.8mWcm−2 for PtTNP:BDP (compound 7),
respectively. Below the respective threshold intensity (Ith), the
upconversion intensity (IUC) and excitation power intensity (Iex) are
in a quadratic relationship. When the Iex exceeds the threshold
intensity, the relationship between IUC and Iex becomes linear
(Supplementary Figs. 12–14).
Next, we measured the photolysis yields of the above-
mentioned TTAP “LEGO” systems (Fig. 2). Specifically, we first
tested the two green light-activating TTAP pairs, including
PtOEP:An (compound 2) and PtOEP:Py (compound 8). We
found that their photolytic yield is outstanding: 83% for An
containing compound 2 and 61% for Py containing compound 8,
respectively, under 20 mW cm-2 532 nm LED light illumination
(Supplementary Tables 5 and 6). In a similar manner, we also
observed significant photolytic yield at 76% and 87% for our far-
red light activating TTAP pairs (PdTPBP:compound 7, PdTPBP:
compound 8), respectively, under 20 mW cm−2 650 nm LED
light irradiation (Supplementary Tables 7 and 8). Moreover, we
tested our NIR light-activating TTAP candidates (PtTNP:
compound 8, PtTNP:compound 7). Notable photolytic yield at
14.7% and 17.7%, respectively, were also observed under 1 h
illumination of 20 mW cm−2 720 nm NIR LED (Supplementary
Tables 9 and 10).
It is exciting that we further found that such low-energy long
wavelength activation can indeed even surpass the traditionally
high-energy short-wavelength light needed direct activation. This
is the case because of the advantages of the TTAP in regard of the
intense long wavelength light absorbance of photosensitizer, the
highly effective TTAP mechanism and the reduced photodamage
on the PPGs-X. For example, in the absence of the photosensitizer
partner, the traditional photolytic reaction on compound 8 with
blue light (445 nm, 20 mW cm−2) only leads to a photolytic yield
of 59% (Supplementary Table 11). In contrast, our TTAP
“LEGO” system (PdTPBP: compound 8) is able to effectively
improve the photolytic yield to 87.1% for compound 8 under a
far-red LED (20 mW cm−2, 650 nm). Furthermore, the photolytic
quantum efficiency (QE) was calculated (see details in “Methods”
section). The resulted QE value gives an overall evaluation with
respect to photolysis reactions, as it considers both the photolysis
quantum yield of PPGs and the absorbance of sensitizers, TTET
and TTA quantum yields (Supplementary Table 12). As a result,
for the PPG of An (compound 2), in conjunction with PtOEP,
QE(TTAP) is calculated to be 1255. For the PtOEP and Py
(compound 8), the QE(TTAP) is calculated to be 708. Moreover, in
conjunction with PdTPBP, the QE(TTAP) is calculated to be 679
for the PPG of Py (compound 8) and QE(TTAP) is 12.3 for BDP
(compound 7), respectively. In addition, the QE(TTAP) is 7.1 for
the PPG of Py (compound 8) and QE(TTAP) is 0.53 for the PPG of
BDP in conjunction with PtTNP, respectively.
Compared to conventionally used protecting groups in peptide
synthesis that are involved with harsh chemical conditions such
as acid/base-sensitive or redox-sensitive groups, PPGs have been
emerging as a traceless and green alternative to allow “reagent-
free” deprotection under light illumination17. Thus, herein we
expanded our TTAP concept to a variety of amino acids such as
glycine, cysteine, and phenylalanine (Fig. 2). As a result, we
observed excellent low power long wavelength light-driven single
photon-mediated deprotection for these amino acids containing
target molecules. For PPGs of An for protecting glycine
(compound 5), we observed the photolytic yield is 58.4% in
conjunction with PtOEP under green LED illumination. For
PPGs of Py for protecting glycine (compound 12), in conjunction
with PdTPBP and PtTNP, the photolytic yield is 89.2%, 29.6%,
respectively. For PPGs of Py for protecting cysteine (compound
14), when PdTPBP and PtTNP are used as photosensitizers, the
photolysis yields are 81.2% and 23.3%, respectively. In addition,
for PPGs of Py for protecting phenylalanine, with PdTPBP and
PtTNP as photosensitizers, the photolytic yields are 70.9% and
29.0%, respectively. These results demonstrated the great
potential of our TTAP technology in a wide array of applications
in relation to functional photocaged amino acids and peptide
synthesis. (Fig. 2)
Having identified our TTAP “LEGO” systems enable photolytic
ester bonds, we then turned our attention to evaluate the scope of
this method with other typically used photolabile linkages of
carbonate (compound 3, compound 9) and carbamate (com-
pound 4, compound 10) in the alcohols and amines containing
targeted molecules. We found that PtOEP:compound 3 and
PtOEP:compound 4 were effectively photolyzed under green light
illumination, respectively, in 72.3%, 51.0% yield. Under far red-
light illumination, PdTPBP:compound 9 and PdTPBP:compound
10 were also efficiently photocleaved. The photolytic yields are
65.3%, 52.4%, respectively (Fig. 2). Moreover, NIR light-activated
TTAP “LEGO”s including PtTNP:compound 9 and PtTNP:
compound 10, were both compatible with this method, affording
27.8%, 29.3% photolytic yield (Fig. 2).
In addition to the above-mentioned amino acids, we also
explored the possibility of extending TTAP compatible targeted
molecules to small molecule drugs in current clinical use. In
particular, small molecule drugs such as anti-inflammatory and
anti-tumor drugs, are known to have severe systematic off-target
side effects18–20. To this end, light-activatable prodrugs constitute
emerging major targets for utilization in drug discovery, due to
their high spatiotemporal resolution in the treatment of complex
diseases21,22. Here, we constructed a series of TTAP compatible
prodrugs via the conjugation of a series of anti-nonsteroidal and
anti-inflammatory drugs (naproxen, indomethacin, ibuprofen)
with perylene via ester bonds (Fig. 2). These resultant compounds
(compounds 16–18) were denoted as pro-naproxen, pro-
indomethacin, and pro-ibuprofen. In conjunction with the far-
red light photosensitizer (PdTPBP) or the NIR light photo-
sensitizer (PtTNP), we observed that pro-naproxen (compound
16) has excellent photolytic reaction yields of 78.5% (PdTPBP)
and 17.4% (PtTNP). For the pro-indomethacin (compound 17),
the photolytic reaction yield is 51.7% (PdTPBP) and 9.2%
(PtTNP). In addition, the photolytic reaction yields are also found
to be quite effective: 71.6% (PdTPBP), and 19.4% (PtTNP) for
pro-ibuprofen (compound 18). The carbonate photolabile linkage
containing pro-cholesterol (compound 20) was also constructed
and can be selectively photolyzed in the yields of 69.4% (PdTPBP)
and 28.6% (PtTNP) under 1 h far-red or NIR light illumination
(Fig. 2).
Designing aqueous soluble TTAP nanoparticles to illustrate
biological applications of TTAP. Next, in order to illustrate the
biological applications via TTAP, we chose chlorambucil, which is
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an FDA approved anti-cancer drug to evaluate the effect of cancer
treatment23. In this regard, we conjugated Py with chlorambucil
to obtain pro-chlorambucil (compound 19). When PdTPBP or
PdTNP were used as the coupling light partners, we observed the
respective photolytic yield of 72.8% (PdTPBP) (Supplementary
Table 14) and 30.4% (PtTNP) (Supplementary Table 15). Fur-
thermore, we studied the relationship between the incident light
intensity and the photolysis yield for the pair of PdTPBP and
compound 19. We compared the photolysis yield under the same
photon flux (36 J cm-2) but with different power density and
experimental duration. As a result, the photolysis yield was found
to be 47% under the higher incident light power density and a
short time duration (20 mW cm−2, 30 min) (Supplementary
Table 14, entry 3). However, the photolysis yield of only 26% was
observed under the lower incident light power density and the
longer duration (10 mW cm−2, 60 min) (Supplementary Table 14,
entry 4). These results suggested that the photolysis yield is light
intensity dependent, thus further supporting our proposed model.
We then designed an oleylamine-substituted amphiphilic poly-
mer (PSMA-PEG-OAm) encapsulated TTAP nanoparticles to
resolve the noxious oxygen quenching of the triplet states of Sen
and PPGs-X under ambient condition (Supplementary Fig. 16).
This unsaturated olefin-modified amphiphilic polymer was found
to be able to encapsulate Sen and PPG-X to form air-stable
monodispersed and water soluble ultra-small sized TTAP nano-
particles (TTAP NPs) (Supplementary Figs. 17–19).
Via 1H NMR spectra and the phosphorescence quenching
experiment (Supplementary Fig. 16), we found that the unsaturated
olefins can react with singlet oxygen to exhaust oxygen from the
stored solution under light illumination. Considering the out-
standing photolytic yield of the combination PdTPBP:compound
19, we prepared TTAP NPs that contain PdTPBP and compound
19. The entrapment and drug-loading efficiency are measured to
be 89% and 16% in TTAP NPs. Via transmission electron
microscope (TEM) and dynamic light scattering (DLS) character-
ization, the TTAP NPs have ultra-small size (12.9 ± 2.6, 29.7 ± 4.6
nm, respectively). Moreover, after 30 days, the size also maintained
at ~30 nm via DLS, suggesting the stability of TTAP NPs
(Supplementary Fig. 17). Via the UV–vis absorption of TTAP
NPs, we further confirmed that TTAP NPs contain PdTPBP and
compound 19 (Supplementary Fig. 18). In addition, after 650 nm
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Fig. 2 Triplet–triplet annihilation-mediated photolytic reactions under diverse low power long wavelength LED irradiation. The superscripts (a–d) next
to the reaction yields represent the sensitizers used and their respective operation light wavelength.
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significant photobleaching, suggesting that TTAP NPs have robust
photostability (Supplementary Fig. 19). We then tested the
photolytic kinetic process of TTAP NPs (Supplementary Figs. 20
and 21). After 60min 20mWcm−2 650 nm LED illumination,
64% prodrug was effectively photolyzed. Moreover, the photolysis
process was clearly dependent on the ON–OFF pattern of the LED
excitation (Supplementary Fig. 21b). These results clearly validated
the feasibility of the use of our TTAP “LEGO” system in aqueous
solution under ambient air. The dose and duration of the prodrug
activation can be precisely interrogated by our TTAP
nanoparticles.
We then conducted in vitro and in vivo studies of our TTAP
NPs. Firstly, via (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) tetrazolium reduction (MTT) assays, we demon-
strated that TTAP NPs significantly enable the inhibition of cancer
cell growth (Supplementary Fig. 22). This result suggests that via
TTAP, the prodrug (pro-chlorambucil) was photolyzed and
released from TTAP NPs into cancer cells, causing cancer cell
death under far red-light illumination. Moreover, we evaluated the
phototoxicity of PdTPBP NPs per se. However, we did not observe
obvious cell death in the presence of the light, suggesting the
negligible phototoxicity of PdTPBP (Supplementary Fig. 23).
Next, we went on to examine the synergistic anti-tumor
immunotherapy effect of our TTAP system in conjunction with
the checkpoint blockade PD-L1 anti-body (α-PD-L1) in a
bilateral model of 4T1 tumor-bearing BALB/c mice24,25. As
shown in Fig. 3a, the tumor on the right represented the primary
tumor that was subjected to the injection of TTAP NPs and the
subsequent light treatment. The tumor on the left was untreated
and served to mimic a distant metastatic tumor. When the tumor
on the right reached 100 mm3, TTAP NPs were intratumorally
injected and this day was named Day 1. After 4 h, this tumor was
exposed to NIR light (650 nm, 20 mW cm−2) for 30 min. At the
7th, 8th, and 9th day, the mice were i.p. injected with the α-PD-
L1 (75 µg per mouse) (Fig. 3b). The therapeutic efficacy of
different treatment groups was evaluated by measuring tumor
volume and weight. The volume growth rates for the tumor on
the right and left are presented, respectively, in Fig. 3c and d. In
group 5 (TTAP NPs+ hv), we only observed that the right tumor
volume was more suppressed than that observed in groups 1–4.
In contrast, for group 6 (TTAP NPs+ hv+ α-PD-L1), both the
right and left tumors volume showed obvious reduction (Fig. 3
and Supplementary Fig. 24). Moreover, after 15 days, the right
and left tumors were isolated and then weighed the tumor mass,
respectively, as shown in Fig. 3e and f, which were consistent with
the growth trend of tumor volume. These experimental results
clearly demonstrated that the TTABP-mediated prodrug photo-
lytic system potentiated the checkpoint blockade immunotherapy
efficacy and promoted abscopal effects.
We next explored the mechanism by which TTAP-mediated
prodrug photolysis enhanced the efficacy of immunotherapy
(Supplementary Figs. 24–27). In particular, we first analyzed
immune cell profiling in the spleen (Supplementary Figs. 25a,
b and 26). The cytotoxic CD8+ T cell and helper CD4+ T cell
levels significantly increased in the treated group, as compared
to those in the PBS treatment group (group 1). After
stimulation with PMA/ionomycin for 4 h, the cytokine of
IFN-γ produced in CD4+ and CD8+ T cells were counted. The
number of antigen-specific IFN-γ-producing T cells signifi-
cantly increased in group 6, suggesting that TTAP plus α-PD-
L1 treatment induced a tumor-specific T cell response. We
further profiled infiltrating leukocytes in the primary and the
distant tumors. Flow cytometry measurements for group
6 showed a significant increase in tumor-infiltration of CD4+
and CD8+ T cells in both primary and distant tumors
(Supplementary Figs. 25c–f and 27). These results demon-
strated TTAP-mediated prodrug plus α-PD-L1 treatment
increased the infiltration of the effector T cells to treat the
metastasis.
We also tested whether there was any in vivo toxicity from
TTAP NPs by measuring the body weight of mice in each cohort
(Supplementary Figs. 28–30 and Supplementary Table 16). The
body weight experiment showed negligible side-effects (Supple-
mentary Fig. 28). Furthermore, we compared the hematoxylin
and eosin (H&E)-stained images of the major organs (heart, liver,
spleen, lung, and kidney) from normal mice to those treated with
TTAP NPs and light. Neither results displayed noticeable organ
damage or inflammation lesions, suggesting that no obvious
heart, liver, spleen, lung, or kidney dysfunction for the mice were
induced by the photoactivatable process using TTAP NPs
(Supplementary Fig. 29). Further, as shown in Supplementary
Table 16, we did not observe abnormal results from the serum
analysis experiments, which suggests that no observable
unwanted inflammation was induced. Excrement from the mice
96 h after an IR806 dye-conjugated TTAP NPs intravenous (i.v.)
injection was also collected. Compared to the PBS-injected
control group, we detected the fluorescence of the IR806 dye
signal in the excrement of mice in the TTAP NPs-treated group
(Supplementary Fig. 30), suggesting that TTAP NPs can be
cleared from the body through the fecal route. Besides, as shown
in Supplementary Fig. 31, in addition to liver, the fluorescence
was also observed at kidney at 10, 24, 48 h and disappeared at 96
and 168 h, suggesting the RGD-TTAP NPs may also be excluded
from the body through kidney, which is similar to other
nanoparticles26,27 (Supplementary Fig. 31). All of these results
demonstrate that the as-designed TTAP NPs possess high
biosafety and are highly biocompatible.
Finally, to achieve targeted tumor therapy, we covalently
conjugated the cyclical Arg-Gly-Asp (cRGD) peptide on the
surface of TTAP NPs (RGD-TTAP NPs) to enhance their tumor
targeting properties (Supplementary Figs. 31 and 32). To verify
the targeted tumor-killing effect of RGD-TTAP NPs in vivo, we
utilized mice bearing a subcutaneous 4T1 tumor xenograft. To
explore the best accumulation time-point of RGD-TTAP NPs in
the tumor tissue, the 4T1 tumor-bearing mice were intravenously
injected with IR806 fluorescence dye modified RGD-TTAP NPs
(IR806-RGD-TTAP NPs) and subjected to in vivo imaging at
different time-points. The fluorescence at the tumor site increased
gradually and reached a maximum level 24 h post-injection. After
48 h, the fluorescence intensity of IR806-RGD-TTAP NPs in the
4T1 tumor gradually decreased. As an additional control, the
cRGD free nanoparticles (IR806-TTAP NPs) were also intrave-
nously injected to mice. However, the IR806-TTAP NPs-treated
mice displayed a much weaker contrast between normal and
tumor tissues (Supplementary Fig. 32b). This result demonstrates
that the cRGD peptide actually improved the targeting to the
tumor of TTAP NPs in our system.
As the accumulation of IR806-RGD-TTAP NPs in the tumor
reached its maximum at 24 h, we then examined the treatment
effect of IR806-RGD-TTAP NPs accompanied by irradiation with
LED (650 nm, 20 mW cm−2) for 30 min. After such treatment,
the therapeutic effects were assessed by monitoring changes in
tumor volume (Supplementary Fig. 32d) as well as by H&E
staining of the tumor tissues (Supplementary Fig. 32f). We only
observed that the tumor growth in the treatment group 6 (IR806-
RGD-TTAP NPs+ hv) was remarkably suppressed. From the
H&E-staining analysis, the tumor tissue also showed clear
necrosis, which indicates that IR806-RGD-TTAP NPs can be
effectively activated by far red LED irradiation for intense
anticancer effect.
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Discussion
In sum, photolytic reaction has powerful and important appli-
cations in numerous aspects of chemistry, materials as well as
biology. Our discovery of long wavelength single photon-driven
TTAP overcomes the key problems (low effectiveness and high
photodamage) in existing methods. This method is “LEGO”-like
and highly modular. The light partners (the photosensitizers and
the PPGs-X) can be energetically matched to adapt to the needs of
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a wide range of electromagnetic spectrum wavelengths and
numerous chemical structures of PPGs, photolabile linkages, and
a broad range of targeted molecules. Moreover, we exemplified
the biological promise of TTAP via creating an ambient air-stable,
ultra-small, water-soluble TTAP nanoparticle. Such nanoparticles
achieve highly effective, ultra-low power, long wavelength single
photon-driven anticancer prodrug activation and, in turn,
potentiated anti-tumor immunotherapeutic responses and pro-
moted abscopal effects.
Methods
Photolytic experiments. The NIR LED (720 nm), far red LED (650 nm), green
LED (530 nm), blue LED (476 nm), and deep blue LED (455 nm) were used for
photolytic reactions. The different pairs of photosensitizers (PtTNP, PdTPBP,
PtOEP, or Ir(ppy)3) and PPGs-X (BDP, perylene, An, or Cou) were degassed for at
least 15 min with argon in THF/H2O (4/1, v/v). Then, the solution was excited with
a LED (20 mW cm−2) at 37 oC. After the photolytic reaction, the raw product was
dried and re-dissolved in CH3CN/H2O= (2/1, v/v) and HPLC was used to analyze
the yield of product.
The Stern–Volmer quenching plot experiment. The photoluminescence of
photosensitizers (PtTNP, PdTPBP, PtOEP, and Ir(ppy)3) in the presence of dif-
ferent concentrations of PPGs including BDP (compound 7), perylene (compound
8), An (compound 2), and Cou (compound 1). The mixed solutions were degassed





where Io and It stand for photoluminescence intensity of photosensitizer in the
absence of PPGs-X and the photoluminescence intensity of photosensitizer in the
presence PPGs-X. Q is the concentration of PPGs-X. Bimolecular quenching
constants (kq) were calculated by the following equation28:
ksv ¼ kq ´ τT
The τT is the phosphorescence lifetime of photosensitizer in argon.
The upconversion quantum yields (ΦUC) calculation12. The upconversion
quantum yields were calculated with the following equation:











where ΦUC and Φstd stand for the upconversion luminescence quantum yield of the
TTA-UC (TTAP 1–6) samples and the fluorescence quantum yield of the reference
compounds, respectively. Aunk and Astd stand for absorbance of the TTA-UC
samples and the reference compound, respectively. Iunk and Istd stand for the
integrated upconversion luminescence intensity of the TTA-UC sample and the
fluorescence intensity of the reference compounds, respectively. ηunk and ηstd stand
for the refractive index of solvents of the TTA-UC samples and the reference
compounds. The solvent used is toluene (ηunk= 1.4967) for all of the TTAP pairs.
The equation is multiplied by a factor of 2 to make the maximum quantum yield of
two unified emitters. For the pairs: (1) PtTNP:BDP; (2) PtTNP:Py, the reference
compound is ZnPc, the fluorescence quantum yield (Φf= 17%) in DMF (ηstd=
1.333). For the pairs of (3) PdTPBP:BDP, (4) PdTPBP:Py, the reference compound
is methylene blue (MB), and its fluorescence quantum yield (Φf= 3%) was mea-
sured in methanol (ηstd= 1.333). For the pairs of (5) PtOEP:Py and (6) PtOEP:An,
the reference compound is rhodamine B, and the fluorescence quantum yield
(Φf= 49%) was measured in ethanol (ηstd= 1.361).
The upconversion experiments was conducted in deaerated solution with argon
for ca. 15 min before each measurement and the argon gas flow was maintained
during the measurement. Please see the respective quantum yield, as follows:
ΦUC (PtTNP/Py)= 0.05%;ΦUC (PtTNP/BDP)= 0.3%;ΦUC (PdTPBP/Py)= 5.8%;
ΦUC (PdTPBP/BDP)= 8.4%; ΦUC (PtOEP/Py)= 9.5%; ΦUC (PtOEP/An)= 8.7%.
Photolytic QE for TTAP systems29. The QE gives a comprehensive evaluation of
photolysis reactions as it considers both photolysis quantum yield of PPGs and
absorbance of sensitizers. We also have considered the TTET and TTA quantum
yields in the calculation.
We can estimate the efficiency of ΦTTET ×ΦTTA by the following formula12:
ΦUC ¼ ΦISC ´ΦTTET ´ΦTTA ´Φf :
In this formula, the ΦISC is the ISC quantum yield of the photosensitizer. ΦTTET is
TTET quantum yield between photosensitizer and annihilator. ΦTTA is quantum
yield of TTA for annihilator. Because TTET and TTA processes are a multi-
molecular intermolecular energy transfer process, so far, there is still a lack of
accurate determination of ΦTTET and ΦTTA. However, we can calculate the result of
ΦTTET ×ΦTTA according to this above formula. The ΦISC for Ir(ppy)314, PtOEP30,
PdTPBP, and PtTNP31 is close to 1, and ΦUC and Φf has been calculated according
to reported protocol.
ΦTTET ×ΦTTA (PtTNP/BDP)= 0.4%,
ΦTTET ×ΦTTA (PtTNP/Py)= 0.06%,
ΦTTET ×ΦTTA (PdTPBP/BDP)= 11.3%,
ΦTTET ×ΦTTA (PdTPBP/Py)= 6.6%,
ΦTTET ×ΦTTA (PtOEP/Py)= 10.9%,
ΦTTET ×ΦTTA (PtOEP/An)= 20.1%.
At last, we considered the TTET and TTA processes to correct photolytic QE
with the following equation:
QE ¼ ε ´Φp ´ΦTTET ´ΦTTA:
QE is the photolytic QE, ε is molar extinction coefficient of sensitizers, and Φp is
photolytic quantum yield of PPGs.
QE (PtTNP/BDP)= 0.53; QE (PtTNP/Py)= 7.1; QE (PdTPBP/BDP)= 12.3;
QE (PdTPBP/Py)= 679; QE (PtOEP/Py)= 708; QE (PtOEP/An)= 1255.
In the UCNPs-assist photolysis, the upconversion quantum yield is low (<0.1%
UV upconversion). Moreover, the LRET efficiency is not high (<10%). Therefore,
these systems not only consider the photolytic quantum yield (Φp) of PPGs, but
also the upconversion quantum yield (Φuc) and LRET (ΦLRET) to get the true
photolytic QE with the following equation:
QE ðupconversionÞ ¼ Φp ´Φuc ´ΦLRET ´ εðPPGÞ:
According to the reported results in the literature32, we calculated photolytic
QE of Cou (QE(Cou)) to be 0.02873 (note: other PPGs including Py, BDP, and An
have not been reported in the literature in combination with UCNPs-assist
photolysis).
Preparation of TTAP NPs. TTAP NPs was prepared via self-assembly of PdTPBP
and compound 19, and PSMA-PEG-OAm with a single-step. Briefly, 0.25 mg
PdTPBP, 20 mg compound 19, and 100 mg PSMA-PEG-OAm were dissolved in 8
mL THF. The mixture was added to 10 mL PBS buffer. The mixed solution was
stirred at 40 °C in dark for 30 min to let THF remove out. In order to absolutely
remove out the THF, we used the air flow to accelerates THF evaporation at 40 °C
for 30 min. Afterward, the TTAP NPs was centrifuged at 6000 × g for 60 min. large
nanoparticles precipitated and the supernatant containing small nanoparticles was
decanted. And then the TTAP NPs solution was purified by dialysis tube (cut off
Mw= 3500). Finally, TTA NPs was stored at 4 °C until use. Similar procedures
were used to prepare the PdTPBP nanoparticles (PdTPBP NPs) and Py nano-
particles (Py NPs).
The entrapment efficiency of dyes in nanoparticles. Firstly, before wrapping the
dyes, we measured the absorbance of dyes in dichloromethane and determined the
initial absorbance of dyes that was fed initially (A0). After encapsulating the dyes
with PSMA-PEG-OAm, the nanoparticles were centrifugated (5000 × g) for 20 min
to attain TTAP NPs. We then added the dichloromethane to extract the dyes from
the nanoparticles, and to test the absorbance (A) to determine the amount of dyes
in TTAP NPs. Then the entrapment efficiency of the dyes was calculated according
to the following equation33.
Fig. 3 TTAP NPs-mediated synergistic immunotherapy. a A schematic illustration of the in vivo study of TTAP NPs-mediated prodrug photoactivation
with checkpoint blockade the α-PD-L1 antibody to realize synergistic immunotherapy in a bilateral model of 4T1 tumor-bearing BALB/c mice. The right-side
tumor stands for primary tumor meanwhile the left side tumor stands for distant tumor or “metastatic tumor”. b A schematic illustration of the
experimental immunotherapy process. At first, the 4T1 cells were seeded at both right back and left back of mice. When the right-side tumor volume
reached to 100mm3, the TTAP NPs was injected into the right-side tumor, which was then illuminated by NIR LED (20mWcm−2, 650 nm). This day was
called as Day 1. At Day 7–9, the α-PD-L1 was intraperitoneally (i.p.) injected for mice of groups 3 and 6. Finally, the tumor of mice was isolated on Day 15.
c The growth curves of primary tumors. d The growth curves of distant tumors. The red arrow stands for i.p. injection α-PD-L1 for groups 3 and 6 at 7th,
8th, and 9th day. e The primary tumor weight of mice. f The distant tumor weight of mice. “G” is the abbreviation of group, values are means ± s.e.m. (n= 5
mice per group). *p < 0.05, **p < 0.01, and ***p < 0.001.
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Entrapment efficiency (%)= absorbance of dyes in nanoparticles (A)/
absorbance of dyes fed initially (A0) × 100.
The PdTPBP entrapment efficiency is 89.0%.
According the entrapment efficiency of prodrug, the mass of prodrug was
calculated in TTAP NPs. The TTAP NPs were also dried by lyophilization and
weight the mass of TTAP NPs.
The prodrug loading efficiency (%)= the mass of prodrug in TTAP NPs /total
mass of TTAP NPs × 100%.
The prodrug loading efficiency of prodrug is calculated to be 16%.
In vitro experiments for TTAP NPs. Human cervical carcinoma (HeLa cell lines)
and mice breast cancer cells (4T1 cell lines) were firstly cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 100
µg mL–1 streptomycin and 100 UmL–1 penicillin at 37 °C in a humidified incubator
containing 5% CO2 and 95% air. The medium was replenished every other day and
the cells were subcultured after reaching confluence. then, the cells (100 μL, 5000)
were plated in a 96-well plate. After 12 h, the nanoparticles were added at different
concentrations (0, 5, 10, 15, 20, 25 μg mL–1). The nanoparticles were taken up over
12 h. The cells were irradiated with far red LED light (650 nm, 20 mW cm–2). After
30 min irradiation, the cells were incubated another 24 h under 5% CO2 atmo-
sphere at 37 °C. MTT solution (5.0 mg mL–1, 50 μL) was added to every well and
left for 4 h. The old cell culture medium was removed carefully and 200 μL DMSO
was added to every well. A microplate reader (Bio-Rad) was used to record the
absorption at 595 nm. And the cell viability was calculated with the following
equation:
Cell viabilityð%Þ ¼ ODvalue test=ODvalue control ´ 100%:
In vivo studies of combination of TTAP NPs with check-point blockade
immunotherapy in 4T1 tumor-bearing mice. (The animal experiments followed
the protocol approved by the Institutional Animal Care and Use Committee
(IACUC), University of Masssachusttes Medical school) The 5 week’s BALB/c
female mice were ordered from Jackson lab. The 4T1 cells (2 × 106) was seeded at
mice right back and the left mice back seeded the 4T1 cells (2 × 105). After the
right-side tumor volume reached to 100 mm3, the 4T1 bearing mice were subjected
to six different treatments: (1) PBS+ hv; (2) PdTPBP+ hv; (3) α-PD-L1 only; (4)
TTAP NPs+ dark; (5) TTAP NPs+ hv; (6) TTAP+ hv+α-PD-L1. The TTAP
NPs (1 mgmL–1, 100 μL) or PdTPBP NPs (10 μg mL–1, 100 μL) was intratumorally
injected in right side tumor in groups 4–6 or group 2, respectively. After 4 h, the
right tumor site was exposed to far red LED (650 nm) for 30 min. The α-PD-L1 (75
μg per mouse) was injected by intraperitoneal during 7−9 day in group 3 and 6.
After 15 days treatment, the mice were euthanized and spleen, right and left tumor
tissues were isolated to analyse the immunity responses. Different treatment groups
were monitored by measuring the right and left tumor sizes using a Vernier caliper
for 15 days. Tumor size=width × width × length/2.
Flow cytometry test of the immune cells in tumors. The tumors (right and left
side) were isolated from the mice after different treatments. The tumor tissue was
divided into small pieces, treated with 1mgmL–1 collagenase I (Gibco) for 1 h at 37 °
C and ground using the rubber end of a syringe (BD, 10mL syringe). Cells were
filtered through nylon mesh filters (Corning, cell strainer, 70 μm nylon). The single
cells were collected by centrifugation (800 × g, 5 min). The blood cells in the tumor
tissue was eliminated by cold NH4Cl lysis. The single suspensions tumor cells were
washed by cold PBS containing 2% FBS. The tumor cells were stained with
fluorescence-labeled antibodies PerCP-Cy™5.5 Hamster Anti-Mouse TCR β chain
(BD bioscience, clone H57-597, catalog No. 560657), PerCP-Cy™5.5 Rat Anti-Mouse
CD3 Molecular Complex Clone (BD bioscience, catalog No. 560527), Pacific Blue™
Rat Anti-Mouse CD45R (clone RA3-6B2, BD bioscience, catalog No. 558108), PE-
Cy™7 Rat Anti-Mouse CD4 (Clone GK1.5, BD bioscience, catalog No. 563933), PE
Rat Anti-Mouse CD8a (Clone 53-6.7, BD bioscience, catalog No. 553032), APC
Mouse Anti-Mouse NK-1.1 (Clone PK136, BD biosciences, catalog No. 561117),
FITC Rat Anti-Mouse CD44 (Clone IM7, BD biosciences, catalog No. 561859), APC-
Cy™7 Rat Anti-Mouse CD62L (Clone MEL-14, BD biosciences, catalog No. 560514)
following the manufacturer’s instructions. All antibodies were diluted 200 times. Flow
cytometric analyses were performed on an LSRFortessa (BD Biosciences) and ana-
lyzed using FlowJo Software (Tree Star). The results are showed as the mean ±
standard error of the mean (s.e.m.) Moreover, Student’s t-test was used for two-group
comparisons. The Origin 9.0 was used for all statistical analyses. The threshold for
statistical significance was ***p < 0.001, **p < 0.01, or *p < 0.05.
Flow cytometry test of the immune cells in the spleen. The spleens were
isolated from the mice after different treatments. We grinded the spleen and
cells, which were then filtered by nylon mesh filters. The blood cells were lysis by
NH4Cl solution twice, and then washed with cold PBS containing 2% FBS. The
single cells were collected by centrifugation (800 × g, 5 min), and the blood cells
in the tumor tissue was eliminated by cold NH4Cl lysis. The cells were incubated
with 50 ng mL−1 PMA (Sigma) and 500 ng mL−1 ionomycin (Sigma) in the
presence of GolgiStop (BD) in complete T cell media at 37 °C for 4 h. Cells were
washed with PBS buffer containing 1% FBS, stained with Live/Dead fixable aqua
dead cell marker (Invitrogen). The following antibodies were used for staining:
PerCP-Cy™5.5 Hamster Anti-Mouse TCR β chain (BD bioscience, clone H57-
597, catalog No. 560657), PerCP-Cy™5.5 Rat Anti-Mouse CD3 Molecular
Complex Clone (BD bioscience, catalog No. 560527), Pacific Blue™ Rat Anti-
Mouse CD45R (clone RA3-6B2, BD bioscience, catalog No. 558108), PE-Cy™7
Rat Anti-Mouse CD4 (Clone GK1.5, BD bioscience, catalog No. 563933), PE Rat
Anti-Mouse CD8a (Clone 53-6.7, BD bioscience, catalog No. 553032), APC
Mouse Anti-Mouse NK-1.1 (Clone PK136, BD biosciences, catalog No. 561117).
Intracellular staining for FITC Rat Anti-Mouse IFN-γ (Clone XMG1.2, BD
biosciences, catalog No. 562019). Intracellular cytokine staining was performed
by fixing cells in 2% paraformaldehyde, followed by permeabilization and
staining (BD Biosciences). Flow cytometric analyses were performed on an
LSRFortessa (BD Biosciences) and analyzed using FlowJo Software (Tree Star).
The results are shown as the mean ± standard error of the mean (s.e.m.)
Moreover, Student’s t-test was used for two-group comparisons. The Origin 9.0
was used for all statistical analyses. The threshold for statistical significance was
***p < 0.001, **p < 0.01, or *p < 0.05.
Preparation of IR806-TTAP NPs. 5 mL TTAP NPs in PBS buffer, 10 mg sodium
sulfonate N-hydroxysuccinimide (NHS.SO3Na), and 10 mg N-(3-dimethylamino-
propyl)-N′-ethylcarbodiimide hydrochloride (EDC.HCl) were added to the nano-
particle solution and the mixture was then stirred at room temperature for 5 h.
After that the amine-substituted IR806 (0.5 mg) was added into the mixture, and
stirred for another 24 h. Finally, the nanoparticles were purified by dialysis (Mw=
12,000).
Body clearance of TTAP NPs. IR806-TTAP NPs were studied in 4T1 tumor-
bearing mice. They were subjected to the following treatments: group 1, intrave-
nous injection of IR806-TTAP NPs (150 μL, 100 μg mL–1); group 2, intravenous
injection of PBS. We collect the mice feces during 48 h, and then measured the
fluorescence of IR806 with IVS animal imaging. Excitation filter was ICG (750–790
nm) and emission filter was ICG (815–850 nm).
Preparation of IR806-RGD-TTAP NPs. 5 mL IR806-TTAP NPs in PBS buffer, 10
mg sodium sulfonate N-hydroxysuccinimide (NHS-SO3Na) and 10 mg
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl) were
added to the nanoparticle solution and the mixture was then stirred at room
temperature for 5 h. After that the cRGD (3mg) was added into the mixture, and
stirred for another 24 h. Finally, the nanoparticles were purified by dialysis (Mw=
120,000).
Tumor-targeted property on subcutaneous 4T1 bearing breast tumor model.
Tumor-targeting property of IR806-TTAP NPs and IR806-RGD-TTAP NPs was
studied in 4T1 tumor-bearing mice. They were subjected to the following
treatments: Group 1: intravenous injection of IR806-RGD-TTAP NPs; Group 2:
intravenous injection of IR806-TTAP NPs. The dose of NPs is 150 μL, 100 μg
mL–1 in saline. We measured the fluorescence of IR806-TTAP NPs and IR806-
RGD-TTAP NPs at different times (10, 24, 48, 96, 168 h) with IVS animal
imaging. Excitation filter was ICG (750–790 nm) and emission filter was ICG
(815–850 nm).
In vivo bio-distribution of IR806-RGD-TTAP NPs. After tail-vein injection of
IR806-RGD-TTAP NPs, the 4T1 tumor-bearing mice were sacrificed, and major
organs including heart, liver, spleen, lung, and kidney were carefully removed for
visualization under the IVS animal imaging system in different time periods (10,
24, 48, 96, and 168 h). The fluorescent signals of each organ were analyzed by the
accompanied software.
In vivo studies of RGD-TTAP NPs for tumor inhibition in 4T1 tumor-bearing
mice. The mice were subjected to six different treatments: PBS control group (group 1),
treatment with light irradiation only (group 2), RGD-TTAP NPs-intravenous injection
only (group 3), TTAP NPs-intravenous injection and then irradiation (group 4),
PdTPBP NPs-intravenous injection and then irradiation (group 5), and RGD-TTAP
NPs-intravenous injection and then treatment with irradiation (group 6). After 24 h,
far-red light LED (650 nm) analysis was performed on groups 2, 4, 5, and 6 at 20mW
cm–2 for 30min. Two mice from each group were euthanized 14 days post-treatment,
and tumor tissues of the above-mentioned treatment groups 1−6 were harvested for
histological study by H&E staining under a BX51 optical microscope (Olympus, Japan)
in a blinded fashion by a pathologist. Different treatment groups were monitored by
measuring the tumor size using a Vernier caliper for 14 days. Tumor size=width ×
width × length/2.
Data availability
The experimental procedures, data, and analysis supporting the conclusions of this work
can be found in the figures and Supplementary Information. Additional data are available
from the corresponding author upon request.
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